James A. Baker, III, and George P. Shultz — both former secretaries of state and Treasury secretaries — offer "A Conservative Answer to Climate Change" in a commentary for The Wall Street Journal.
James A. Baker, III, George P. ShulzFebruary 15, 2017
High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.
Baker Institute experts blog on opportunities for the U.S. and Mexico to jointly address the neglected tropical diseases found among the poorest people living in both countries.
Peter J. Hotez, Jennifer R. Herricks, Kirstin R.W. MatthewsSeptember 28, 2015
In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.
In physics, extensive collaborations, access to colleagues’ data and rigorous peer review make it extremely difficult for individual researchers to bend the rules. Furthermore, physics does not harbor the types of ethical minefields characteristic of the biosciences. No thorny questions arise pertaining to human or animal life, nor do physicists commonly grapple with the ethical haze of intellectual property when patents and money are at stake. Things seem to be black and white in physics. But are they?
Elaine Howard Ecklund, Kirstin R.W. MatthewsJune 1, 2015
Drug policy has experienced an interesting shift recently. Along with legalization of medical and recreational marijuana, many states are also reducing penalties for nonviolent drug offenses and placing greater focus on treatment for drug users. The emphasis on treatment and rehabilitation for drug users is the result of many factors, including recognition that the drug war has not reduced drug use, a desire to reduce the prison population and save money, and a surge in the rate of overdoses from opioid and heroin use. What remains to be seen is whether the current popularity of drug treatment will become a more permanent feature of drug policy. In this Baker Institute Viewpoints series, five experts on drug policy examine the question, “Is the current emphasis on treatment in drug policy a short-term trend or is it here to stay?”
Katharine Neill Harris, William MartinDecember 19, 2014
It is inconceivable to imagine our nation today without the gains of the Civil Rights Act. It is impossible to understand why the issue was so divisive then, since it is such an obvious right and moral proposition. Similarly, let us hope we will look back at the Affordable Care Act 20 years from now and wonder why it was such a contentious topic in 2014.